Navigation Links
Chimerix Initiates Phase 1 Study of CMX157
Date:5/13/2010

CMX157 is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology to chemically modify tenofovir, the molecule underlying the prodrug Viread®, an antiviral agent approved for the treatment of HIV and chronic hepatitis B. Chimerix's PIM Conjugate Technology improves the absorption and distribution profile of drugs, achieving higher intracellular levels of the active antiviral agent. In vivo toxicology studies show that high plasma levels of CMX157 can be achieved with minimal toxicities.

CMX157 represents Chimerix's second antiviral compound to enter the clinic. Chimerix's lead compound, CMX001, a broad-spectrum antiviral agent with demonstrated in vitro activity against double-stranded DNA viruses, is in a multi-center Phase 2 clinical trial in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV) and is also in clinical development for the treatment of BK virus in renal transplant and stem cell transplant recipients.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on th
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
2. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
6. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
7. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
8. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
9. EnVivo Initiates Phase IIb Alzheimers Disease Trial For EVP-6124
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Pipette.com has ... to their comprehensive portfolio of Eppendorf products. , ... to purchase a Centrifuge 5424/5424 R and receive the ... either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... , RESEARCH TRIANGLE PARK, N.C., July 22 ... it has completed its acquisition of Stiefel Laboratories, Inc. GSK has ... $2.9 billion. GSK also assumed $0.4 billion of net debt. ... additional cash payments of up to $0.3 billion depending on the future ...
... DUBAI, United Arab Emirates and SAN FRANCISCO, July 22 ... serving the Middle East, Africa, Turkey & Caspian regions, today ... supply agreement with Axcan Pharma for Pylera (R) , an ... pylori , a bacterium now recognized as being the main ...
... , CHICAGO, July 22 ... annual meeting today indicates that monitoring cardiac transplant patients with ... help clinicians to monitor cyclosporine-induced toxicity and adjust doses of ... , , In a scientific ...
Cached Biology Technology:GlaxoSmithKline Completes Acquisition of Stiefel 2NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 2NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 3Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... the familiar semi-aquatic bugs gliding across the lake at the ... walk on water. This was not always the case. ... unique arrangement of the legs, with the mid-legs greatly elongated. ... Evolutionary Biology have discovered the gene behind this evolutionary change. ...
... human brain distinctly separates the handling of images of ... image type in a different area of the brain. ... visual information in this manner to optimize processing the ... people who have been blind since birth the brain ...
... Sandbar, dusky and tiger sharks are among dozens of ... East Coast. Little is known about many of the species, ... scientists and fishery resource managers to monitor shark populations and ... Northeast Fisheries Science Center (NEFSC) lab in Narragansett, R.I., recently ...
Cached Biology News:Brain innately separates living and non-living objects for processing 2Scientists conduct shark survey off US East Coast 2Scientists conduct shark survey off US East Coast 3
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... Pfx DNA Polymerase is ideal for ... downstream applications such as cloning and ... by a proprietary enzyme preparation containing ... with proofreading (3'Cut Site5' exonuclease) activity. ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
... offers precision beveling of micropipette ... The unique abrasive plate drive ... greater control of the beveling ... very rapidly and produces consistent ...
Biology Products: